HYPOLIPIDEMIC EFFECTS OF TRIGONELLA FOENUM-GRAECUM (FENUGREEK) SEED POWDER ADMINISTRATION IN RABBITS WITH EXPERIMENTAL DIETARY HYPERLIPIDEMIA
The present study is designed to investigate the efficacy of the most common dietary component fenugreek (seed powder) consumption on dietary dyslipidemia and its comparison with atorvastatin. Twenty Four white rabbits of either sex were used in the study. After one week acclimatization period, animals were randomly divided into two groups. Group I animals received normal diet. Group II animals were administered with atherogenic diet for four weeks. Group II is than subdivided as Group II-a: 10mg of fenugreek seed powder were fed daily to these hyperlipidemic animals for next 15 days and Group II-b: hyperlipidemic animals receive 0.5mg/Kg BW of atorvastatin for 15 days. At the end of experimental period blood specimens were obtained and assayed for alterations in plasma lipid profile (TC, TG, HDL, LDL, VLDL), atherogenic index, glucose, antioxidant enzymes (CAT, SOD, GSH), liver enzymes (AST, ALT) and plasma levels of urea & creatinine. The results of the present study showed that administration of atherogenic diet increase plasma lipid profile, glucose, liver enzymes, urea and creatinine while decrease antioxidant enzymes in experimental animals. Administration of fenugreek seed powder reduce plasma levels of TC (P>0.05), TG (P<0.05). LDL-C (P>0.05), VLDL (P<0.05), AIP (P>0.05) and increase HDL levels (P>0.05) hence effectively control AIP. Glucose levels were also decreased (P>0.05), FsP administration significantly decrease plasma AST (P<0.005), ALT (P<0.01), urea (P<0.05) and creatinine levels (P<0.005). Fenugreek consumption significantly improve body antioxidant status by increasing plasma SOD (P<0.005), CAT (P>0.05) and GSH (P<0.05) levels in hyperlipidemic animals. From obtained results it is suggested that daily supplementation of fenugreek seeds effectively reduces dietary hyperlipidemia and other risk factors of CAD.